Understanding Peptide Impurities

Impurity Origins in SPPS

Solid-phase peptide synthesis (SPPS) proceeds through iterative cycles of Fmoc deprotection and amino acid coupling. Each cycle has an efficiency of 97–99.5%, depending on the coupling chemistry and sequence context. For a 20-mer peptide at 99% per-cycle efficiency, the theoretical yield of full-length product is ≈ 82.6%. The remaining ~17% consists of deletion sequences, truncated peptides, and other impurities.

Truncated Sequences

Truncated peptides terminate prematurely when the growing chain fails to couple the next amino acid. Common causes:

• Steric hindrance at bulky residues (e.g., Ile, Val, Leu at position ) that resist aminolysis by the incoming aminoacyl fluoride or HOBt-ester.
• Incomplete deprotection — residual Fmoc groups block the α-amino group, preventing the next coupling step.
• Incomplete coupling — substoichiometric activator (HBTU, HATU) or degraded amino acid building blocks.

Truncated sequences typically elute earlier in RP-HPLC than the target (they are more hydrophilic, having fewer hydrophobic residues).

Deletion Sequences

A deletion peptide is missing one or more internal residues. These arise when a coupling step fails but subsequent cycles proceed normally—they are a specific subclass of truncated sequences where the chain re-initiates after the failed coupling. Deletion peptides are particularly problematic because their mass and hydrophobicity closely match the target, making chromatographic separation difficult. A deletion of Ala (Δ71 Da) vs. the target may shift the RP-HPLC retention time by <0.5 minutes.

Oxidation Products

Oxidation occurs during synthesis, purification, storage, or reconstitution:

Residue	Oxidation Product	ΔMass (Da)	Conditions	Biological Impact
Met	Methionine sulfoxide	+16	Dissolved O₂, peroxides, metal ions	Reduced hydrophobicity; loss of hydrophobic interactions
Met	Methionine sulfone	+32	Stronger oxidation	Irreversible; altered conformation
Trp	Oxindolylalanine	+16	UV light, radicals, O₂	Loss of π-stacking; reduced receptor affinity
Cys	Cystine (disulfide)	+1 (per S-S bond)	Air, basic pH	Cross-linking; aggregation
His	2-oxo-histidine	+16	Metal-catalyzed Fenton chemistry	Disrupted metal coordination; loss of catalytic activity

Aggregation

Peptide aggregation is a thermodynamically driven process where monomeric peptides associate through:

• Hydrophobic interactions — nonpolar side chains (Leu, Ile, Val, Phe) cluster to minimize contact with water.
• Hydrogen bonding — formation of intermolecular β-sheet structures, particularly in sequences with alternating hydrophobic/hydrophilic residues.
• Disulfide bonds — covalent cross-linking between Cys residues (irreversible under non-reducing conditions).
• Electrostatic interactions — charge-charge attraction between peptides with complementary net charges at a given pH.

Aggregates appear as insoluble particles, turbidity, or high-molecular-weight shoulders on analytical SEC or DLS profiles. Aggregated peptides may have reduced activity (epitope burial), altered pharmacokinetics (different clearance rates), or immunogenic potential (neoepitopes exposed at aggregate surfaces).

Incomplete Deprotection

Residual protecting groups remaining after TFA cleavage:

• Trifluoroacetylation — TFA adducts on Lys ε-amino or Ser/Thr hydroxyl groups. These are typically removed by repeated ether precipitation but may persist at low levels.
• Incomplete side chain deprotection — Residual Pbf (Arg), tBu (Asp, Glu, Ser, Thr), Boc (Lys, Trp) groups. Detected by mass spectrometry (+mass shift corresponding to the protecting group).
• Capping byproducts — Acetyl or formyl groups from side reactions during synthesis.

These impurities alter peptide charge state, solubility, and receptor binding specificity.

HPLC Analysis

Reversed-Phase HPLC Principles

RP-HPLC separates peptides by hydrophobicity. The stationary phase (C18 or C8 bonded silica) retains hydrophobic peptides; the mobile phase (water/acetonitrile gradient with 0.1% TFA) elutes them in order of increasing organic solvent concentration.

Column: C18, 5 μm particle size, 100 Å pore size, 4.6 × 250 mm (analytical) or 2.1 × 100 mm (UHPLC).

Mobile phase:

• Solvent A: H₂O + 0.1% TFA (v/v)
• Solvent B: CH₃CN + 0.1% TFA (v/v)
• Gradient: Typically 10–90% B over 30 minutes for analytical, 5–60% B over 10 minutes for UHPLC.

Detection: UV absorbance at 214 nm (peptide bond π→π* transition, ε ≈ 7,500 M⁻¹cm⁻¹ per bond) and 280 nm (aromatic residues, particularly Trp ε₂₈₀ ≈ 5,600 M⁻¹cm⁻¹).

Interpreting Chromatograms

Peak Position	Likely Identity	Typical Cause
Earlier eluting (lower %B)	Truncated/deletion sequences, free amino acids	Synthesis failure
Main peak	Target peptide	—
Shoulder on main peak	Closely-eluting deletion or modification	Incomplete coupling, oxidation
Later eluting (higher %B)	Aggregates, hydrophobic modifications	Aggregation, non-specific modifications

Purity by area normalization:

Purity Thresholds

Purity	Application	Impurity Considerations
>95%	Standard research (binding assays, cell culture)	Minor impurities unlikely to confound most assays
>98%	Quantitative pharmacology, dose-response studies	Reduced risk of competitive inhibition by truncated sequences
>99%	Structure-activity relationships, crystallography	Minimal interference with binding or structural measurements
>99.5%	Pharmaceutical development	Regulatory-grade; impurities individually characterized

Critical caveat: Purity percentage alone is insufficient. A 95% pure peptide containing 5% of a competitive antagonist will produce dramatically different results than the same peptide with 5% of an inactive truncated sequence. Always identify the major impurities, not just their total percentage.

Mass Spectrometry Confirmation

HPLC purity confirms the quantity of a single species relative to others, but does not confirm the identity of that species. Mass spectrometry provides the molecular weight of each eluting peak.

ESI-MS (Electrospray Ionization)

Soft ionization that produces multiply charged ions: . The observed values are deconvoluted to obtain the molecular mass. Resolution: typically 10,000–100,000 (Orbitrap, Q-TOF).

Expected accuracy: ±0.01% for high-resolution instruments (e.g., 2,000 Da peptide → ±0.2 Da).

MALDI-TOF

Matrix-assisted laser desorption/ionization produces singly charged ions . Higher tolerance of impurities and salts than ESI. Resolution: 5,000–20,000.

Common Artifacts

Artifact	Mass Shift	Source
Sodium adduct	+22.990 Da	Na⁺ contamination in solvents/glassware
Potassium adduct	+38.964 Da	K⁺ contamination
TFA adduct	+114.010 Da	Incomplete TFA removal during purification
Dehydration	-18.011 Da	Asp-Pro cleavage or Ser/Thr loss
Oxidation	+15.995 Da	Met or Trp oxidation

Certificate of Analysis (CoA)

A CoA provides manufacturer-verified quality data for a specific lot:

Field	What to Check
Sequence	Confirm matches your target
MW (theoretical)	Cross-reference with your sequence calculation
MW (observed, MS)	Should match theoretical within instrument accuracy
Purity (HPLC)	Meets experimental requirements
Appearance	White to off-white powder (color may indicate oxidation)
Solubility	Confirms recommended solvent
Storage	Temperature and handling conditions
Lot number	Match to vial label; retain for traceability

Use the CoA to: (1) verify lot number matches your vial, (2) confirm purity meets your experimental threshold, (3) cross-check observed MW against theoretical, (4) note any manufacturer-specific storage conditions. File the CoA with your laboratory records. Analytical-grade testing supplies and reference standards from Kingston Peptides support rigorous quality control.

Impact on Research Outcomes

Bioactivity Interference

• Competitive inhibitors — Truncated peptides may bind the target receptor without activating it, shifting dose-response curves rightward and reducing apparent potency.
• Agonist impurities — A deletion peptide with residual activity at a different receptor can produce off-target effects that confound mechanistic studies.
• Altered pharmacokinetics — Aggregated or oxidized peptides have different clearance rates, tissue distribution, and metabolic stability.

Reproducibility

Lot-to-lot purity variation is a major source of inter-experiment variability. If results are inconsistent between batches, (1) verify purity of each lot by HPLC, (2) confirm molecular weight by MS, and (3) consider re-purifying or switching lots.

Storage-Related Purity Degradation

Stress Factor	Degradation Pathway	Rate Dependence	Mitigation
Temperature	Hydrolysis (Asp-Pro, Asn-Gly bonds), oxidation	Arrhenius: ~2× rate per 10°C increase	Store at -20°C or colder
Moisture	Hydrolysis, aggregation, microbial growth	Water activity >0.3 accelerates degradation	Desiccant, sealed containers
Light	Photooxidation (Trp, Tyr, Met)	Cumulative, wavelength-dependent	Amber vials, aluminum foil wrap
Oxygen	Oxidation (Met, Cys, Trp)	Proportional to dissolved O₂	Flush headspace with N₂ or Ar
Freeze-thaw	Aggregation, denaturation	Per cycle; cumulative damage	Aliquot single-use volumes

For long-term studies (>6 months), perform periodic HPLC analysis of stored aliquots to monitor purity trends. Visual inspection (cloudiness, color change) detects gross degradation but misses subtle chemical modifications.

---

For research use only. Verify peptide purity and identity before critical experiments.